1 / 5

Clinical Management of Chronic Stable Angina

Clinical Management of Chronic Stable Angina. Anti-ischemic strategies in stable CAD. Initial therapy. Medical therapy PCI CABG. Recurrent ischemia.  Antianginal drug therapy (uptitrate/add new agents). Repeat revascularization (if possible). TMR EECP SCS.

Mercy
Télécharger la présentation

Clinical Management of Chronic Stable Angina

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Management of Chronic Stable Angina

  2. Anti-ischemic strategies in stable CAD Initial therapy Medical therapy PCI CABG Recurrent ischemia Antianginal drug therapy(uptitrate/add new agents) Repeat revascularization (if possible) TMR EECP SCS TMR = transmyocardial revascularization EECP = enhanced external counterpulsation SCS = spinal cord stimulation Gibbons RJ et al. ACC/AHA 2002 guidelines. http://www.acc.org/clinical/guidelines/stable/stable.pdf.

  3. Older antianginal drugs: Pathophysiologic effects O2 Supply O2 Demand Coronary blood flow Heart rate Arterial pressure Venous return Myocardial contractility Drug class β-blockers DHP CCBs Non-DHP CCBs Long-acting nitrates * / Boden WE et al. Clin Cardiol. 2001;24:73-9.Gibbons RJ et al. ACC/AHA 2002 guidelines. www.acc.org/clinical/guidelines/stable/stable.pdf Kerins DM et al. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. CCB = calcium channel blocker DHP = dihydropyridine *Except amlodipine

  4. Older antianginal drugs: Clinical conditions that may limit use *Treated with PDE5 inhibitors †Nondihydropyridine CCBs Gibbons RJ et al. ACC/AHA 2002 guidelines. www.acc.org/clinical/guidelines/stable/stable.pdf

  5. “Unmet needs” in antianginal therapy • Despite medical therapy and/or revascularization, some patients continue to experience angina • Current treatment options for recurrent angina are limited • Consensus on role of newer treatments is pending • How best to manage symptomatic patients?

More Related